Aspirin Improve Survival of N2-3 Nasopharyngeal Carcinoma Patients
Status:
Not yet recruiting
Trial end date:
2024-09-30
Target enrollment:
Participant gender:
Summary
Nasopharyngeal carcinoma (NPC) is one of the most common maligancies of China. In the era of
intensity-modulated radiotherapy (IMRT), the 5-year overall survival (OS) has now reached
85.0% or more. However, even after chemoradiation, the 5-year distant-metastasis rate of
patients with N2-3 NPC is still 36.7%. Aspirin is proven in lab and clinical studies to have
the abilities of inhibiting the inflammation which could enhance metastasis of breast and
colorectal cancers. And before this study, it was discovered that regular aspirin intake
might be associated with distant-metastasis-free survival (MFS) and OS independently. So this
Phase 2 trial was conducted to validate the impact of aspirin on prognosis of N2-3 NPC.